Poor
Substantially Misaligned
Patient Risk:
Medium
Summary
Multiple claims about food/snacking effects on absorption, grapefruit limits, and quantitative pharmacokinetics (e.g., 14% bioavailability) are unsupported by the provided label excerpts. While the label supports dosing with or without food and grapefruit juice increasing atorvastatin levels, several other details are absent or contradicted by what is provided.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can be taken once daily at any time, with or without food.
Section 2.1: “administered as a single dose at any time of the day, with or without food”.
Grapefruit juice inhibits CYP3A4 and raises Lipitor (atorvastatin) levels.
Section 7.2: “inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin”.
Unsupported Statements
Lipitor (atorvastatin) has no restrictions on snacking.
No label excerpt provided addresses snacks or restrictions beyond “with or without food” dosing and grapefruit juice interaction.
Food does not affect Lipitor (atorvastatin) absorption or effectiveness.
The provided label excerpt supports dosing with or without food (Section 2.1) but does not state that food has no effect on absorption or effectiveness.
Lipitor’s pharmacokinetics remain stable regardless of meals, including snacks high in fat or calories.
No label excerpt provided contains statements about meal composition, fat/calorie snacks, or pharmacokinetic stability.
Atorvastatin’s bioavailability is about 14%.
No provided label excerpt gives a numerical bioavailability value.
Atorvastatin bioavailability is unaffected by gastric pH.
No provided label excerpt states effects (or lack of effects) of gastric pH on bioavailability.
Atorvastatin bioavailability is unaffected by food.
No provided label excerpt states that bioavailability is unaffected by food.
Consistent LDL reduction occurs whether atorvastatin is taken with meals or snacks.
The provided label excerpts do not link lipid efficacy outcomes to meal/snack timing.
Increased Lipitor (atorvastatin) levels from grapefruit juice may increase muscle pain risk.
The label excerpt provided for grapefruit juice states plasma concentration increases, but the provided excerpts do not connect grapefruit-induced level increases to muscle pain risk.
Grapefruit juice should be limited to small amounts (under 1 quart daily) when taking Lipitor (atorvastatin).
The label excerpt provides a threshold of “>1.2 liters per day” for excessive grapefruit juice consumption (Section 7.2), not “under 1 quart daily,” and “1 quart” is not stated in the provided label.
There are no issues with other snacks such as chips, nuts, or fruit while taking Lipitor (atorvastatin).
No provided label excerpt addresses chips/nuts/fruit or snack-specific safety.
Contradictions
Low
AI Statement
Grapefruit juice should be limited to small amounts (under 1 quart daily) when taking Lipitor (atorvastatin).
Label Reference
Section 7.2: “especially with excessive grapefruit juice consumption (>1.2 liters per day).”
Important Omissions
For grapefruit juice: the label-specific threshold “>1.2 liters per day” is not reflected accurately in the claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported snack/food-effect claims could lead to false reassurance, and the grapefruit juice limit is inaccurately expressed versus the provided label threshold (>1.2 liters/day). The label does support that grapefruit juice can increase atorvastatin plasma concentrations via CYP3A4 inhibition.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Substantially Misaligned
Primary Issue
Multiple pharmacokinetic/food-snack quantitative and categorical claims are not supported by the provided label excerpts; grapefruit juice quantity guidance is not consistent with the label-provided threshold.
Suggested Improvement
Restrict statements to label-supported dosing (“single dose at any time… with or without food”) and grapefruit interaction (“inhibit CYP 3A4” and “especially with excessive grapefruit juice consumption >1.2 liters/day”). Remove or qualify unsupported statements about bioavailability (e.g., 14%), gastric pH effects, meal composition stability, and snack categories.